Results 1 to 10 of about 4,421 (195)

Degludec insulin: A novel basal insulin

Indian Journal of Endocrinology and Metabolism, 2011
This paper reviews a novel insulin analogue, degludec, which has the potential to emerge as an ideal basal insulin. It reviews the limitations of existing basal insulin and analogues, and highlights the need for a newer molecule.
Sanjay Kalra, Ambika Gopalakrishnan Unnikrishnan, Manash Baruah, Bharti Kalra   +3 more
doaj   +4 more sources

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin? [PDF]

Clinical Medicine Insights: Endocrinology and Diabetes, 2012
The advances in recombinant DNA technology have led to an improvement in the properties of currently available long-acting insulin analogs. Insulin degludec, a new generation ultra-long-acting basal insulin, currently in phase 3 clinical trials, has a ...
L Raymond Reynolds
exaly   +3 more sources

A FAERS database study on visual impairment adverse events associated with three long-acting insulin analogues [PDF]

Frontiers in Endocrinology
PurposeTo utilize the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) to systematically evaluate and compare the risk signals, clinical characteristics, and potential influencing factors of visual impairment adverse events (AEs ...
Li Zhong, Wenxuan Cao, Xinyu Liu, Tiancai Wen, Jing Yan   +4 more
doaj   +2 more sources

Use of insulin degludec in pregnancy: two case reports and a literature review

Endocrine and Metabolic Science, 2020
As of now, insulin Degludec has no indication for use in pregnancy, because of the lack of studies that prove its safety for foetus. However it isn't infrequent that some women conceive while treating with insulin Degludec.
Elisa Sprio
exaly   +3 more sources

Transition from Continuous Subcutaneous Insulin Infusion to IDeg-Based Regimens in Hospitalized T2DM Patients: A Single-Center Retrospective Analysis [PDF]

Diabetes, Metabolic Syndrome and Obesity
Ruiqing Dong,1,* Lifan Gu,2,* Heping Li,1 Yuanna Hu,3 Hui Liu,4 Xuna Kou,1 Yukun Zhao,1 Meng Zhao,1 Bingyin Shi,1 Hui Guo,1 Wei Qiang1 1Department of Endocrinology and Metabolism, The First Affiliated Hospital of Xi’an Jiaotong University,
Dong R, Gu L, Li H, Hu Y, Liu H, Kou X, Zhao Y, Zhao M, Shi B, Guo H, Qiang W   +10 more
doaj   +2 more sources

Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials

Journal of Diabetes Investigation, 2021
Aims/Introduction To assess efficacy and safety of insulin degludec/liraglutide (IDegLira) in Japanese participants with type 2 diabetes across different baseline characteristics. Materials and Methods Data from two randomized controlled trials were used:
Mitsuhisa Komatsu, Hirotaka Watada, Shizuka Kaneko, Bue F Ross Agner, Tomoyuki Nishida, Kohei Kaku   +5 more
doaj   +1 more source

One-year safety and effectiveness of insulin degludec in patients with diabetes mellitus in routine clinical practice in India—TRUST (Tresiba real-world use study)

Metabolism Open, 2022
Objective: This post-authorization safety study (PASS) was conducted to evaluate the long-term safety and effectiveness of insulin degludec in patients with diabetes mellitus (DM) requiring insulin therapy in routine clinical practice in India.
Jothydev Kesavadev, L.Sreenivasa Murthy, Tirthankar Chaudhury, Sadasiva Rao Yalamanchi, J. Giri, Sunil Gupta, Sanjeev Phatak, K.D. Modi, Sanjay Chatterjee, Aparna Manjunath, Manjunatha Revanna, Arpandev Bhattacharya   +11 more
doaj   +1 more source

DUAL I China:在一项对未服用口服降糖药物的中国2型糖尿病患者进行的随机试验中, IDegLira与其单独成分相比改善了血糖控制

Journal of Diabetes, 2022
Background DUAL I China, one of the DUAL trials, assessed efficacy/safety of insulin degludec/liraglutide (IDegLira) in Chinese adults with type 2 diabetes (T2D) not controlled by oral antidiabetic drugs (OADs).
Weiqing Wang, Bue F. Ross Agner, Bin Luo, Lei Liu, Ming Liu, Yongde Peng, Shen Qu, Karolina Amelia Stachlewska, Guixia Wang, Guoyue Yuan, Qiu Zhang, Guang Ning   +11 more
doaj   +1 more source

Basal insulin titration algorithms in patients with type 2 diabetes: the simplest is the best (?)

Mìžnarodnij Endokrinologìčnij Žurnal, 2023
Basal insulin is the first and main component of insulin therapy in patients with type 2 diabetes mellitus (T2DM). Based on the shortcomings of human NPH insulin and the advantages provi­ded by long-acting basal insulin analogues, they are recommended ...
V.I. Katerenchuk
doaj   +1 more source

Comparison of efficacy of detemir and degludec insulin in the management of children and adolescents with type 1 diabetes

Journal of Diabetology, 2022
Aims and Objectives: Despite the advantages offered by current basal analogs, the management of type 1 diabetes (T1D) in children and adolescents is a great challenge till now.
Bedowra Zabeen, Bulbul Ahmed, Nasreen Islam, Samin Tayyeb, Jebun Nahar, Kishwar Azad   +5 more
doaj   +1 more source